Cordlife Group (SGX:P8A) ROCE %: -3.92% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SGX:P8A Cordlife Group Ltd SGX:P8A
38 GF Score
Price S$0.15
GF Value S$0.17
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Cordlife Group ROCE %?

Cordlife Group SGX:P8A +6.43% 38 ROCE % is -3.92% as of Mar. 2026. GuruFocus rates SGX:P8A with a GF Score™ of 38/100 and a GF Value™ of S$0.17 (Modestly Undervalued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cordlife Group's annualized ROCE % for the quarter that ended in Mar. 2026 was -3.92%.

Cordlife Group  (SGX:P8A) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cordlife Group ROCE % Related Terms

Cordlife Group ROCE % Historical Data

* Premium members only.

The historical data trend for Cordlife Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cordlife Group ROCE % Chart

Cordlife Group Annual Data
Trend Jun15 Jun16 Jun17 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.46 2.71 2.20 -9.58 -6.01

Cordlife Group Quarterly Data
Mar19 Jun19 Sep19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.42 -5.93 -5.14 -9.71 -3.92
SGX:P8A
38GF Score
Cordlife Group Ltd SGX:P8A
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cordlife Group ROCE % Calculation

Cordlife Group's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-10.847/( ( (217.142 - 28.93) + (201.759 - 28.936) )/ 2 )
=-10.847/( (188.212+172.823)/ 2 )
=-10.847/180.5175
=-6.01 %

Cordlife Group's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-6.7/( ( (201.759 - 28.936) + (200.477 - 31.17) )/ 2 )
=-6.7/( ( 172.823 + 169.307 )/ 2 )
=-6.7/171.065
=-3.92 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -3.92% mean?
Cordlife Group (SGX:P8A) has a ROCE % of -3.92% as of Mar. 2026.
Is Cordlife Group's ROCE % too high?
Cordlife Group's current ROCE % is -3.92%. Overall, Cordlife Group has a GF Score™ of 38/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cordlife Group's ROCE % compare to TMO and DHR?
Cordlife Group's ROCE % of -3.92% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Diagnostics & Research company?
A good ROCE % depends on the Medical Diagnostics & Research industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Cordlife Group's current ROCE % is -3.92%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cordlife Group stock overvalued right now?
Based on GuruFocus' analysis, Cordlife Group (SGX:P8A) is currently considered Modestly Undervalued. The stock's GF Value™ is S$0.17, compared to a current price of S$0.15 — trading 12.4% below its estimated fair value. The current ROCE % is -3.92%. Cordlife Group's overall GF Score™ is 38/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Cordlife Group (SGX:P8A), the current ROCE % is -3.92% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cordlife Group (SGX:P8A) Overvalued in 2026?

Based on GuruFocus' analysis, Cordlife Group stock appears to be undervalued. The current stock price of S$0.15 is trading 12.4% below its estimated GF Value™ of S$0.17. GuruFocus considers Cordlife Group to be Modestly Undervalued.

Key valuation signals for SGX:P8A:

  • ROCE %: -3.92%
  • GF Value™: S$0.17 vs. price of S$0.15 (12.4% below fair value)
  • GF Score™: 38/100 with 4 warning signs

No single metric tells the full story. See the SGX:P8A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cordlife Group Business Description

Other Exchanges CLIFF:USA
Address 1 Kim Seng Promenade, No. 15-01, Great World City East, Singapore, SGP, 237994
Cordlife Group Ltd is a consumer healthcare company dedicated to safeguarding the well-being of mother and child. Along with its subsidiaries, the company is engaged in the provision of diagnostics and cord blood banking services, which involve the processing and storage of cord blood stem cells. The group has two reportable segments as follows: the Banking segment, which derives maximum revenue, comprises the collection, processing, and banking of biological materials; and the Diagnostics segment, which comprises diagnostics testing services. Geographically, the group generates maximum revenue from Hong Kong, and the rest from the Philippines, India, Malaysia, Singapore, and other regions.
38GF Score

Get the complete analysis for SGX:P8A

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

S$0.15
Price
S$0.17
GF Value